[
  {
    "ts": null,
    "headline": "Is Bristol Myers Squibb (BMY) Pricing Reflecting Its Recent Share Price Rebound?",
    "summary": "If you are wondering whether Bristol-Myers Squibb is attractively priced right now, this article will walk through what the current share price could mean for long term investors. The stock last closed at US$60.77, with returns of 8.7% over 7 days, 8.8% over 30 days, 13.7% year to date, 15.0% over 1 year, negative 4.8% over 3 years, and 23.5% over 5 years. These figures give important context for any value discussion. Recent coverage has focused on Bristol-Myers Squibb's position in large...",
    "url": "https://finnhub.io/api/news?id=2c3f6bf72201de5124936be50acacce5dbd4cf27c69ec3b03c541994a430cf51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770740115,
      "headline": "Is Bristol Myers Squibb (BMY) Pricing Reflecting Its Recent Share Price Rebound?",
      "id": 139033564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you are wondering whether Bristol-Myers Squibb is attractively priced right now, this article will walk through what the current share price could mean for long term investors. The stock last closed at US$60.77, with returns of 8.7% over 7 days, 8.8% over 30 days, 13.7% year to date, 15.0% over 1 year, negative 4.8% over 3 years, and 23.5% over 5 years. These figures give important context for any value discussion. Recent coverage has focused on Bristol-Myers Squibb's position in large...",
      "url": "https://finnhub.io/api/news?id=2c3f6bf72201de5124936be50acacce5dbd4cf27c69ec3b03c541994a430cf51"
    }
  },
  {
    "ts": null,
    "headline": "Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?",
    "summary": "BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.",
    "url": "https://finnhub.io/api/news?id=70152b51779bd9a533304b4d0ef9fe5769184f1cd54b14f1fbce71453ee519b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770739560,
      "headline": "Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?",
      "id": 139033468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.",
      "url": "https://finnhub.io/api/news?id=70152b51779bd9a533304b4d0ef9fe5769184f1cd54b14f1fbce71453ee519b2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY) Is Up 8.7% After Profit Rebound And Pipeline Outlook - Has The Bull Case Changed?",
    "summary": "Bristol-Myers Squibb recently reported its fourth-quarter and 2025 results, showing broadly stable annual revenue of about US$48.19 billion and a swing from a prior-year net loss to net income of US$7.05 billion, alongside improved earnings per share from continuing operations. Management’s upbeat guidance, stronger performance from its growth portfolio, and plans for multiple pivotal late-stage trial readouts in 2026 have renewed attention on the company’s product pipeline and its efforts...",
    "url": "https://finnhub.io/api/news?id=fe9ec06a27e36915e0d636c7dc20ed6bcfe7ddb4ceb2560c3e1905b729630ef2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770725492,
      "headline": "Bristol-Myers Squibb (BMY) Is Up 8.7% After Profit Rebound And Pipeline Outlook - Has The Bull Case Changed?",
      "id": 139029651,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb recently reported its fourth-quarter and 2025 results, showing broadly stable annual revenue of about US$48.19 billion and a swing from a prior-year net loss to net income of US$7.05 billion, alongside improved earnings per share from continuing operations. Management’s upbeat guidance, stronger performance from its growth portfolio, and plans for multiple pivotal late-stage trial readouts in 2026 have renewed attention on the company’s product pipeline and its efforts...",
      "url": "https://finnhub.io/api/news?id=fe9ec06a27e36915e0d636c7dc20ed6bcfe7ddb4ceb2560c3e1905b729630ef2"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "summary": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
    "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770702333,
      "headline": "Gilead Sciences: Buy This Stock For Both Dividend And Growth",
      "id": 139028076,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e81d72ae20afbebf3fb8841caae7adbb69cb25fe0e1e1f62e222e0a30a1acee9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb AI Trials And 2026 Readouts Reframe Valuation",
    "summary": "Bristol Myers Squibb (NYSE:BMY) has entered a partnership with Evinova to use AI tools in clinical trial design and execution. The company is focusing this collaboration on speeding up and refining development across its drug pipeline. Analysts have recently updated success probabilities for several key pipeline therapies, reflecting closer attention to upcoming programs. Management has highlighted 2026 as a year with multiple pivotal clinical data readouts expected across major...",
    "url": "https://finnhub.io/api/news?id=cdd5e1049029f5105d73d1a66469da992251240b2d49bfe0db5a7d4afcdab869",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770689523,
      "headline": "Bristol Myers Squibb AI Trials And 2026 Readouts Reframe Valuation",
      "id": 139026165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (NYSE:BMY) has entered a partnership with Evinova to use AI tools in clinical trial design and execution. The company is focusing this collaboration on speeding up and refining development across its drug pipeline. Analysts have recently updated success probabilities for several key pipeline therapies, reflecting closer attention to upcoming programs. Management has highlighted 2026 as a year with multiple pivotal clinical data readouts expected across major...",
      "url": "https://finnhub.io/api/news?id=cdd5e1049029f5105d73d1a66469da992251240b2d49bfe0db5a7d4afcdab869"
    }
  }
]